Form 4: Upstream Bio Director, Harold Edward Fleming, Acquires Stock Options
SEC Form 4
Harold Edward Fleming, a director of Upstream Bio, Inc., acquired stock options for 17,096 shares on October 10, 2024, though he disclaims beneficial ownership as he holds them for Enavate Sciences, LP.
Summary
- On October 10, 2024, Harold Edward Fleming, a director of Upstream Bio, Inc., acquired stock options for 17,096 shares.
- The exercise price of these options is $17.
- The options vest on the earlier of October 10, 2025, or the date of the next Annual Meeting of Stockholders, contingent upon continued service as a director.
- Fleming disclaims beneficial ownership of these options and the underlying shares, as he holds them for the benefit of Enavate Sciences, LP.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of directors with those of the shareholders.
Stakeholder Impact
- The grant of stock options to a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 10/10/2024 | Date of stock option transaction |
| 10/10/2025 | Earliest vesting date for the stock options |
| 10/09/2034 | Expiration date of the stock options |
| 10/15/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.